Literature DB >> 1698732

Mapping of linear epitopes of human papillomavirus type 16: the E1, E2, E4, E5, E6 and E7 open reading frames.

J Dillner1.   

Abstract

Certain types of human papillomavirus (HPV), especially HPV type 16, are associated with proliferative lesions of the cervix uteri that can progress to malignancy. In order to map the linear epitopes of the HPV-encoded proteins, we have synthesized the predicted amino acid sequences of the open reading frames (ORFs) in the early region of HPV 16, as a set of 94 synthetic 20-residue peptides overlapping each other with 5 amino acids. The peptides were tested for reactivity with IgA, IgG and IgM antibodies in the sera of 30 patients with HPV 16-carrying cervical neoplasia. The EI ORF had only low immunoreactivity, but several relatively minor epitopes were identified in the carboxyterminal part. The E2 ORF was found to contain several epitopes that were highly immunoreactive with a majority (up to 87%) of the cervical cancer patients' sera. The E4 ORF had one major, regularly IgA- and IgG-reactive epitope, whereas the E5 and E6 ORFs had only a few minor epitopes. The E7 ORF had several epitopes that were highly immunoreactive, but only with a minority of patients' sera. The 10 most immunoreactive peptides were also analyzed for immunoreactivity with 60 control sera, of which 22 were derived from patients with parotid gland tumors and 38 were derived from healthy volunteers. Most of the peptides were also immunoreactive with the control sera. However, the IgA antibodies, and to some extent the IgG antibodies, were found at much lower levels among the controls.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698732     DOI: 10.1002/ijc.2910460426

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  General Assessment of Humoral Activity in Healthy Humans.

Authors:  Phillip Stafford; Daniel Wrapp; Stephen Albert Johnston
Journal:  Mol Cell Proteomics       Date:  2016-02-22       Impact factor: 5.911

Review 2.  Multiplicity of uses of monoclonal antibodies that define papillomavirus linear immunodominant epitopes.

Authors:  A B Jenson; M C Jenson; L Cowsert; S J Ghim; J P Sundberg
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

3.  Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA-binding domains.

Authors:  J M Gauthier; J Dillner; M Yaniv
Journal:  Nucleic Acids Res       Date:  1991-12       Impact factor: 16.971

4.  Prevalence and risk factors for neutralizing antibodies to human papillomavirus types 16 and 18 in HIV-positive men who have sex with men.

Authors:  Rachna Sharma; Jimmy T Efird; Aung Chein; Elizabeth A Holly; Mel Krajden; J Michael Berry; Teresa M Darragh; Naomi Jay; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-15       Impact factor: 3.731

Review 5.  Pathobiology of papillomavirus-related cervical diseases: prospects for immunodiagnosis.

Authors:  C P Crum; S Barber; J K Roche
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

6.  Levels of immunoglobulin G antibodies against defined epitopes of the L1 and L2 capsid proteins of human papillomavirus type 6 are elevated in men with a history of condylomata acuminata.

Authors:  A Wikström; C Eklund; G Von Krogh; P Lidbrink; J Dillner
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

7.  Predominance of serum antibodies to synthetic peptide stemming from HPV 18 open reading frame E2 in cervical adenocarcinoma.

Authors:  M Lehtinen; A Leminen; J Paavonen; P Lehtovirta; H Hyöty; E Vesterinen; J Dillner
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

8.  Development of type-specific and cross-reactive serological probes for the minor capsid protein of human papillomavirus type 33.

Authors:  C Volpers; M Sapp; C A Komly; P Richalet-Secordel; R E Streeck
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Antibodies against papillomavirus antigens in cervical secretions from condyloma patients.

Authors:  L Dillner; A Fredriksson; E Persson; O Forslund; B G Hansson; J Dillner
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

10.  Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix.

Authors:  P Lenner; J Dillner; F Wiklund; G Hallmans; U Stendahl
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.